Skip to main content

Table 3 Treatment comparisons for 10 min post challenge mean TNSS and mean nasal PIF over the last three days of the allergen challenge series.

From: Effects of a dual CCR3 and H1-antagonist on symptoms and eosinophilic inflammation in allergic rhinitis

Variable

Treatment

Mean differencea

95% CI

P-value

TNSS

AZD3778 vs. placebo

-1.56

-2.03, -1.09

<0.001

 

Loratadine vs. placebo

-1.87

-2.34, -1.4

<0.001

 

AZD3778 vs. loratadine

0.312

-0.149, 0.773

0.181

Nasal

PIF

AZD3778 vs. placebo

16.8

5.73, 27.9

0.004

 

Loratadine vs. placebo

8.67

-2.43, 19.8

0.124

 

AZD3778 vs. loratadine

8.14

-2.83, 19.1

0.143

  1. aAdjusted mean difference from ANOVA.
  2. AZD3778 as well as loratadine reduced post challenge TNSS. In addition, AZD3778 improved post challenge nasal PIF.